政策干预与医药上市公司创新绩效的关联性分析

Relevance Analysis of Policy Intervention and Innovation Performance of Pharmaceutical Listed Companies

随着人们生活水平提高和对健康的重视,医药行业越来越受到人们的关注。作为典型的知识密集型行业,医药企业需要不断地研究开发生产新的产品来满足市场需求,但由于药品研发周期长、风险高,很多医药企业均倾向于生产仿制药品,降低对研发的投入,以此谋求利润,导致我国医药企业的自主创新能力有很大上升空间。目前,我国医药行业的科技研发能力普遍得到加强,医药产业政策对于鼓励科研能力做出了很大贡献,但近年来仍然不稳定,并且呈下降趋势;同时政府支持干预与医药上市企业创新绩效具有正向关联性。

With the improvement of people’s living standard and the emphasis on health, the pharmaceutical industry has attracted more and more attention. As a typical knowledge-intensive industry, pharmaceutical enterprises need to constantly research and develop new products to meet market demand. However, due to the long cycle and high risk of drug research and development, many pharmaceutical enterprises tend to produce generic drugs and reduce investment in research and development(R&D) for seeking profits, which leads to a great increase in the independent innovation ability of Chinese pharmaceutical enterprises. At present, the R&D capability of Chinese pharmaceutical industry has been generally strengthened, and the policy of pharmaceutical industry has made a great contribution to encouraging R&D capability. However, in recent years, it is still unstable and showing a downward trend. At the same time, the government support intervention has a positive correlation with the innovation performance of pharmaceutical listed enterprises.